Table 1 Baseline demographic and clinical characteristics in the dilution cohort and stratified by genetic GBA1 status

Sex, male, n (%)

181 (69.6)

158 (71.8)

23 (57.5)

Age at visit, years^a

66.8 (57.0–72.4)

67.6 (59.4–73.3)

58.6 (53.2–67.6)

Age at onset, years^a

59.0 (51.0–65.0)

60.0 (51.3–67.0)

51.0 (45.5–60.0)

Disease duration at first sampling, years^a

6.0 (2.8–10.1)

5.9 (2.7–10.0)

6.2 (4.1–10.2)

Time from first visit to last visit, months^a

56.0 (21.0–104.5)

53.5 (19.3–108.0)

81.0 (30.5–102.5)

Time from baseline to last visit, months^a

25.0 (0.0–61.0)

25.0 (0.0–66.0)

26.0 (8.0–47.0)

H&Y^a

2.0 (2.0–2.5)

2.0 (2.0–2.5)

2.0 (2.0–3.0)

UPDRS part III^a

25.0 (17.0–33.0)

25.0 (17.0–33.0)

28.0 (18.0–36.0)

MoCA^a

26.0 (22.0–28.0)

26.0 (22.0–28.0)

27.5 (22.0–29.0)

BDI II^a

8.0 (4.0–14.0)

8.0 (4.0–14.0)

8.0 (3.0–13.0)

LEDD^a

534 (300–850)

534 (300–836)

485 (285–916)

Sniffin sticks (%)^a

41.7 (29.2–62.5)

41.7 (33.3–66.7)

45.8 (14.6–58.3)

Presence of RBD^b

111/225 (49.3)

89/189 (47.1)

22/36 (61.1)

Presence of hyposmia^b

70/74 (94.6)

60/64 (93.8)

10/10 (100)

Presence of hallucinations^b

60/244 (24.6)

50/206 (24.3)

10/38 (26.3)

Presence of orthostatic hypotension^b

112/244 (45.9)

92/209 (44.0)

20/35 (57.1)

Presence of constipation^b

128/251 (51.0)

106/213 (49.8)

22/38 (57.9)

Presence of urge^b

157/248 (63.3)

129/212 (60.8)

28/36 (77.8)

Presence of malignant phenotype^b,c

13/68 (19.1)

11/59 (18.6)

2/9 (22.2)

Presence of motor wearing-off^b

25/199 (12.6)

14/165 (8.5)

11/34 (32.4)

Presence of dyskinesias^b

23/178 (12.9)

16/145 (11.0)

7/33 (21.2)

Presence of freezing of gait^b

31/197 (15.7)

18/161 (11.2)

13/36 (36.1)

Presence of repeated falls^b

47/214 (22.0)

36/178 (20.2)

11/36 (30.6)

log₁₀SD50/ml^a

1.14 (0.89–1.39)

1.14 (0.91–1.38)

1.16 (0.86–1.40)